Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) Shares Outstanding (Weighted Average) (2017 - 2025)

Cue Biopharma (CUE) has disclosed Shares Outstanding (Weighted Average) for 9 consecutive years, with $20.5 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) fell 63.54% to $20.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.5 million through Dec 2025, down 63.54% year-over-year, with the annual reading at $20.5 million for FY2025, 244.36% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $20.5 million in Q4 2025 for Cue Biopharma, down from $12435.6 billion in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $12435.6 billion in Q1 2024 to a low of $789358.0 in Q2 2022.
  • Historically, Shares Outstanding (Weighted Average) has averaged $1243.6 billion across 5 years, with a median of $31.3 million in 2021.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): skyrocketed 116005288.51% in 2024 and later tumbled 100.0% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $31.3 million in 2021, then increased by 13.95% to $35.6 million in 2022, then tumbled by 95.7% to $1.5 million in 2023, then skyrocketed by 3578.13% to $56.3 million in 2024, then plummeted by 63.54% to $20.5 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CUE at $20.5 million in Q4 2025, $12435.6 billion in Q3 2025, and $95.5 million in Q2 2025.